Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / articles / JNJ - Johnson & Johnson Cancer Drug Rybrevant Shows Improvement In Broader Lung Cancer Population | Benzinga

JNJ - Johnson & Johnson Cancer Drug Rybrevant Shows Improvement In Broader Lung Cancer Population | Benzinga

Johnson & Johnson

Janssen, a unit of Johnson & Johnson (NYSE: JNJ), released topline results from the three-arm Phase 3 MARIPOSA-2 study evaluating Rybrevant (amivantamab-vmjw) regime versus chemotherapy alone, targeting epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET).

The Rybrevant regime includes with and without lazertinib combined with chemotherapy (carboplatin and pemetrexed).

MARIPOSA-2 enrolled patients ...

Full story available on Benzinga.com
Stock Information
Company Name: Johnson & Johnson
Stock Symbol: JNJ
Market: NYSE
Website: jnj.com
Menu
JNJ JNJ Quote JNJ Short JNJ News JNJ Articles JNJ Message Board
Get JNJ Alerts

News, Short Squeeze, Breakout and More Instantly...